Novartis expands in gene therapy and neuroscience with $8.7 billion acquisition

9 April 2018
mergers-acquisitions-big

Flush with cash following the $13 billion sale of its consumer health joint venture stake, Swiss pharma giant Novartis (NOVN: VX) has announced a significant acquisition to expand its gene therapy and neuroscience business.

Novartis has reached an agreement and plan of merger with AveXis (Nasdaq: AVXS) to acquire the US-based clinical stage gene therapy company AveXis for $218 per share or a total of $8.7 billion in cash. AveXis shares closed down 3.o9% at $115.91 on Friday. Novartis’s shares rose 0.75% to 78.26 Swiss francs at 10.40 am in Zurich trading.

This offer represents a premium of 88% to AveXis’ closing price on April 6, 2018, and a 72% premium to the company's 30-day volume-weighted average stock price, according to the US company. The transaction, which is expected to close mid-2018, was unanimously approved by the boards of directors of both companies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology